Why did SLNO's EPS remain flat in recent quarters?

Soleno Therapeutics' (SLNO) EPS has remained relatively flat in recent quarters due to a combination of factors:

1. **Revenue Growth**: The lack of revenue growth last year could be a contributing factor to the flat EPS. Revenue growth is crucial for the sustainability and success of any company, and its absence might indicate that the company is not yet profitable or is struggling to generate income.
2. **Strategic Alternatives**: The company is exploring strategic alternatives, which might include acquisitions, mergers, divestitures, or licensing agreements. Such activities can divert attention and resources away from regular business operations, potentially impacting financial performance.
3. **Insider Activity**: There has been a trend of insider selling, with significant transactions by CFOs and the CEO. Insider selling can be a signal to investors about the confidence that insiders have in the company's future performance. However, it is important to consider that insiders may sell for personal reasons unrelated to the company's financial health.
4. **Market Conditions**: The biopharmaceutical sector is highly competitive and sensitive to market conditions. Changes in market conditions, regulatory environments, or competitive landscapes can impact a company's financial performance and profitability.

In summary, Soleno Therapeutics' flat EPS in recent quarters can be attributed to a combination of factors including lack of revenue growth, strategic alternatives, insider activity, and market conditions.